Cargando…
Routes of non-traditional entry into buprenorphine treatment programs
BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972002/ https://www.ncbi.nlm.nih.gov/pubmed/31959194 http://dx.doi.org/10.1186/s13011-020-0252-z |
_version_ | 1783489832230584320 |
---|---|
author | Champagne-Langabeer, Tiffany Swank, Michael W. Langabeer, James R. |
author_facet | Champagne-Langabeer, Tiffany Swank, Michael W. Langabeer, James R. |
author_sort | Champagne-Langabeer, Tiffany |
collection | PubMed |
description | BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared with no treatment. Although the use of buprenorphine as an agonist treatment for opioid use disorder (OUD) is growing significantly, barriers remain which can prevent or delay treatment. In this study we examine non-traditional routes which could facilitate entry into buprenorphine treatment programs. METHODS: Relevant, original research publications addressing entry into buprenorphine treatment published during the years 1989–2019 were identified through PubMed, PsychInfo, PsychArticles, and Medline databases. We operationalized key terms based on three non-traditional paths: persons that entered treatment via the criminal justice system, following emergencies, and through community outreach. RESULTS: Of 462 screened articles, twenty studies met the inclusion criteria for full review. Most studies were from the last several years, and most (65%) were from the Northeastern region of the United States. Twelve (60%) were studies suggesting that the criminal justice system could be a potentially viable entry route, both pre-release or post-incarceration. The emergency department was also found to be a cost-effective and viable route for screening and identifying individuals with OUD and linking them to buprenorphine treatment. Fewer studies have documented community outreach initiatives involving buprenorphine. Most studies were small sample size (mean = < 200) and 40% were randomized trials. CONCLUSIONS: Despite research suggesting that increasing the number of Drug Addiction Treatment Act (DATA) waived physicians who prescribe buprenorphine would help with the opioid treatment gap, little research has been conducted on routes to increase utilization of treatment. In this study, we found evidence that engaging individuals through criminal justice, emergency departments, and community outreach can serve as non-traditional treatment entry points for certain populations. Alternative routes could engage a greater number of people to initiate MOUD treatment. |
format | Online Article Text |
id | pubmed-6972002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69720022020-01-27 Routes of non-traditional entry into buprenorphine treatment programs Champagne-Langabeer, Tiffany Swank, Michael W. Langabeer, James R. Subst Abuse Treat Prev Policy Review BACKGROUND: Excessive prescribing, increased potency of opioids, and increased availability of illicit heroin and synthetic analogs such as fentanyl has resulted in an increase of overdose fatalities. Medications for opioid use disorder (MOUD) significantly reduces the risk of overdose when compared with no treatment. Although the use of buprenorphine as an agonist treatment for opioid use disorder (OUD) is growing significantly, barriers remain which can prevent or delay treatment. In this study we examine non-traditional routes which could facilitate entry into buprenorphine treatment programs. METHODS: Relevant, original research publications addressing entry into buprenorphine treatment published during the years 1989–2019 were identified through PubMed, PsychInfo, PsychArticles, and Medline databases. We operationalized key terms based on three non-traditional paths: persons that entered treatment via the criminal justice system, following emergencies, and through community outreach. RESULTS: Of 462 screened articles, twenty studies met the inclusion criteria for full review. Most studies were from the last several years, and most (65%) were from the Northeastern region of the United States. Twelve (60%) were studies suggesting that the criminal justice system could be a potentially viable entry route, both pre-release or post-incarceration. The emergency department was also found to be a cost-effective and viable route for screening and identifying individuals with OUD and linking them to buprenorphine treatment. Fewer studies have documented community outreach initiatives involving buprenorphine. Most studies were small sample size (mean = < 200) and 40% were randomized trials. CONCLUSIONS: Despite research suggesting that increasing the number of Drug Addiction Treatment Act (DATA) waived physicians who prescribe buprenorphine would help with the opioid treatment gap, little research has been conducted on routes to increase utilization of treatment. In this study, we found evidence that engaging individuals through criminal justice, emergency departments, and community outreach can serve as non-traditional treatment entry points for certain populations. Alternative routes could engage a greater number of people to initiate MOUD treatment. BioMed Central 2020-01-20 /pmc/articles/PMC6972002/ /pubmed/31959194 http://dx.doi.org/10.1186/s13011-020-0252-z Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Champagne-Langabeer, Tiffany Swank, Michael W. Langabeer, James R. Routes of non-traditional entry into buprenorphine treatment programs |
title | Routes of non-traditional entry into buprenorphine treatment programs |
title_full | Routes of non-traditional entry into buprenorphine treatment programs |
title_fullStr | Routes of non-traditional entry into buprenorphine treatment programs |
title_full_unstemmed | Routes of non-traditional entry into buprenorphine treatment programs |
title_short | Routes of non-traditional entry into buprenorphine treatment programs |
title_sort | routes of non-traditional entry into buprenorphine treatment programs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972002/ https://www.ncbi.nlm.nih.gov/pubmed/31959194 http://dx.doi.org/10.1186/s13011-020-0252-z |
work_keys_str_mv | AT champagnelangabeertiffany routesofnontraditionalentryintobuprenorphinetreatmentprograms AT swankmichaelw routesofnontraditionalentryintobuprenorphinetreatmentprograms AT langabeerjamesr routesofnontraditionalentryintobuprenorphinetreatmentprograms |